Nine e-posters showcase efficacy and safety data for botulinum neurotoxin serotype E and onabotulinumtoxinA treatments.
Allergan Aesthetics, an AbbVie company, presented new clinical data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress in Paris, France, Jan 29-31.
The company showcased nine e-posters featuring data on its botulinum neurotoxin treatments, hyaluronic acid (HA)-based fillers, and a filler with biostimulatory properties. The presentations included pooled Phase 3 efficacy, safety, and patient satisfaction data for trenibotulinumtoxinE, a botulinum neurotoxin serotype E currently under regulatory review.
“Allergan Aesthetics is driving the future of aesthetic medicine through a focus on scientifically driven innovation,” says John Maltman, vice president, global aesthetics medical affairs, Allergan Aesthetics, in a release. “At IMCAS 2026, we’re unveiling new research that addresses patient concerns and offers health care providers new insight to on-market and emerging treatment options across neurotoxin, biostimulatory, and HA filler modalities.”
TrenibotulinumtoxinE Clinical Data
Four poster presentations focused on trenibotulinumtoxinE, which delivers rapid results with a short-duration of effect for patients with glabellar lines. The data included age-related efficacy outcomes, treatment results in male participants, patient-reported outcomes from a Phase 3 randomized trial, and efficacy and safety regardless of prior botulinum toxin use.
One study examined treatment satisfaction and natural-looking results, showing that the novel botulinum neurotoxin serotype E delivered high treatment satisfaction and improved appearance-related psychological impact for glabellar lines treatment.
Additional research demonstrated that trenibotulinumtoxinE maintained efficacy and safety for glabellar lines treatment regardless of patients’ prior botulinum toxin use, based on pooled Phase 3 analysis data.
OnabotulinumtoxinA Research Results
Two Phase 4 studies of onabotulinumtoxinA for upper facial lines highlighted the benefits of long-term use and patient satisfaction with natural outcomes. The research included subgroup findings examining treatment satisfaction and natural-looking outcomes by participant sex.
A global retrospective chart review and cross-sectional study identified motivating factors for long-term repeated onabotulinumtoxinA treatment for upper facial lines, providing insights into patient treatment patterns and preferences.
Additional Portfolio Data
The presentations also included evaluation of a hyaluronic acid and calcium hydroxyapatite hybrid injectable, examining its mechanism of action. Researchers assessed satisfaction and aesthetic outcomes in the periorbital region following treatment with hyaluronic acid injectables and onabotulinumtoxinA in Asian participants.
One poster explored multimodal approaches to skin rejuvenation, covering techniques from epidermal hydration to dermal biostimulation using the company’s AA Signature approach.
Allergan Aesthetics also hosted two educational symposia at the conference, featuring global experts discussing botulinum toxin developments and the AA Signature multimodal treatment approach.
The company maintained an interactive booth allowing attendees to explore its portfolio and connect with medical experts.
ID 216269128 © Thiago Rocha Dos Santos | Dreamstime.com
